GeoVax.
biotechnology company
- Reports this week
- 0
- Active events
- 0
- Connections
- 47
What's happening
Gone quiet
No new reports in 90+ days-
GeoVax, a company targeting infectious diseases including Lassa, began trading on the NASDAQ stock exchange on July 1, 2026.Some support2 reports
-
Renaissance Technologies bought a new stake in GeoVax.Some support2 reports
-
FDA approval affirms GeoVax's therapeutic strategy.Speculative1 report
-
GeoVax announced its patent in Atlanta, utilizing CSP protein in its vaccine design, with David Dodd serving as CEO.Speculative1 report
-
GeoVax is seeking an offering through the SEC, with Roth Capital Partners serving as the exclusive placement agent.Speculative1 report
-
An Mpox surge across Africa is underway, with Clade I variants emerging. The EMA has given favorable scientific advice for the Geo-MVA vaccine candidate, amidst heavy impacts in DRC and Malawi.Some support2 reports2 developments inside
-
GeoVax Labs, based in Atlanta, announced its vaccine addresses outbreaks in Central Africa following favorable EMA input.Speculative1 report
-
GeoVax announced results from Atlanta on July 22, 2025.Some support1 report
-
GeoVax is advancing Gedeptin into a combination trial, and Kelly McKee serves as the Chief Medical Officer at the company.Some support1 report
-
GeoVax initiated a research program at the University of Queensland.Some support1 report
-
GeoVax, led by CEO David Dodd, received SA from EMA for its GEO-MVA and presented at a conference in New York City on September 3, 2025.Some support9 reports
-
HHS terminated mRNA vaccine contracts and Kennedy criticized vaccine limitations, while GeoVax data covers Wuhan strain through Omicron.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around GeoVax this week
News at the entities that move GeoVax most-
FDA StructuralAn industrial event related to a manufacturing crisis is triggering regulatory clocks overseen by the FDA.Moves GeoVax
-
European Medicines Agency StructuralMenarini Group and NewAmsterdam Pharma Company N.V. are collaborating on drug development, seeking marketing authorization in Europe through the EMA and EC process.Moves GeoVax
-
Renaissance Technologies TransactionalRenaissance Technologies raised its stake in shares of Star Equity Holdings, Inc. on August 25, 2026.Moves GeoVax
-
UNICEF TransactionalUNICEF is supporting the provision of desalination and wells to improve water access in Gaza City.Moves GeoVax
-
Saudi Arabia TransactionalAnkara and Saudi Arabia signed a Memorandum of Understanding (MoU) to cooperate on electricity.Moves GeoVax
-
MarketBeat Mentioned togetherMarketBeat is aggregating consensus ratings for Cytokinetics, while Bank of America provided a neutral rating and Morgan Stanley raised its target price.Moves GeoVax
Connections
The 14 strongest of 47, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Renaissance Technologies Transactional
Renaissance Technologies purchased a new stake in GeoVax.
-
Pratima Kumari Structural
Pratima Kumari is employed as a scientist on GeoVax's team.
-
David Dodd Structural
David Dodd serves as the Chairman and CEO of GeoVax.
-
FDA Structural
The FDA provides regulatory approvals and guidance that fundamentally determines GeoVax's therapeutic strategy and market viability.
-
EMA Structural
EMA provides regulatory guidance and scientific advice that influences GeoVax's product development and approval path.
-
UNICEF Transactional
GeoVax is actively targeting national stockpiles, including those managed or utilized by UNICEF, for potential future business transactions.
-
European Medicines Agency Structural
EMA granted GeoVax an expedited pathway for clinical trials, establishing a regulatory dependency.
-
Saudi Arabia Transactional
GeoVax is currently targeting Saudi Arabia's national stockpiles as a potential buyer for its products.
Show all 14 connections
-
MarketBeat Mentioned together
MarketBeat aggregates analyst sentiment data specifically tracking the performance and outlook of GeoVax.
-
Lassa Shared context
GeoVax is a company developing vaccine candidates targeting Lassa disease.
-
Italy Shared context
GeoVax conducted clinical data presentations at an EHA meeting held in Milan, Italy.
-
Nasdaq Shared context
GeoVax is a company that trades on the Nasdaq stock exchange.
-
Atlanta Shared context
GeoVax conducts its operations, announcements, and research within the geographical context of Atlanta, GA.
-
Alena Kohušová Mentioned together
No direct evidence linking GeoVax and Alena Kohušová was found in the provided snapshots.
History
Events by the month they beganJuly 2026
1 eventJune 2026
11 events- Renaissance Technologies bought a new stake in GeoVax.
- FDA approval affirms GeoVax's therapeutic strategy.
- GeoVax announced its patent in Atlanta, utilizing CSP protein in its vaccine design, with David Dodd serving as CEO.
- GeoVax is seeking an offering through the SEC, with Roth Capital Partners serving as the exclusive placement agent.
- An Mpox surge across Africa is underway, with Clade I variants emerging. The EMA has given favorable scientific advice for the Geo-MVA vaccine candidate, amidst heavy impacts in DRC and Malawi.
- GeoVax Labs, based in Atlanta, announced its vaccine addresses outbreaks in Central Africa following favorable EMA input.
- GeoVax announced results from Atlanta on July 22, 2025.
- GeoVax is advancing Gedeptin into a combination trial, and Kelly McKee serves as the Chief Medical Officer at the company.
- GeoVax initiated a research program at the University of Queensland.
- GeoVax, led by CEO David Dodd, received SA from EMA for its GEO-MVA and presented at a conference in New York City on September 3, 2025.
- HHS terminated mRNA vaccine contracts and Kennedy criticized vaccine limitations, while GeoVax data covers Wuhan strain through Omicron.